69238-1722 : Etravirine 200 mg Oral Tablet
NDC: | 69238-1722 |
Labeler: | Amneal Pharmaceuticals Ny LLC |
Product Type: | Human Prescription Drug |
Drug Name: | Etravirine |
Dosage Form: | Oral Tablet |
Application #: | ANDA214196 |
Rev. Date: |
NDC Package Codes:
- 69238-1722-6: 60 TABLET IN 1 BOTTLE, PLASTIC (69238‑1722‑6)
Active Ingredients:
- Etravirine
Dosage Strength:
- 200 mg
Pharmaceutical Classes:
- Cytochrome P450 2C19 Inhibitors [MoA]
- Cytochrome P450 2C9 Inhibitors [MoA]
- Cytochrome P450 3A Inducers [MoA]
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
- Non-Nucleoside Analog [EXT]
- Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
- P-Glycoprotein Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 69238-1720 Etravirine 25 mg Oral Tablet by Amneal Pharmaceuticals Ny LLC
- 69238-1721 Etravirine 100 mg Oral Tablet by Amneal Pharmaceuticals Ny LLC
- 60219-1720 Etravirine 25 mg Oral Tablet by Amneal Pharmaceuticals Ny LLC
- 60219-1721 Etravirine 100 mg Oral Tablet by Amneal Pharmaceuticals Ny LLC
- 60219-1722 Etravirine 200 mg Oral Tablet by Amneal Pharmaceuticals Ny LLC
- 42291-473 Etravirine 100 mg Oral Tablet by Avkare
- 42291-474 Etravirine 200 mg Oral Tablet by Avkare
- 69315-285 Etravirine 100 mg Oral Tablet by Leading Pharma, LLC
- 69315-286 Etravirine 200 mg Oral Tablet by Leading Pharma, LLC
- 80005-112 Etravirine 100 mg Oral Tablet by Carnegie Pharmaceuticals LLC
- 80005-113 Etravirine 200 mg Oral Tablet by Carnegie Pharmaceuticals LLC
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 69238-1721Next: 69238-1729 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.